Beta Bionics (BBNX) CCO Mark Hopman Sells Shares

What Happened
Mark Hopman, Chief Commercial Officer of Beta Bionics (BBNX), reported an open‑market sale of 30,779 shares on 2026-09-16. The transaction disposed of shares at a weighted average price of $20.1319, generating roughly $619,640 in proceeds. This was a sale (code S), which is often routine rather than a bullish signal.

Key Details

• Transaction date: 2026-09-16 (reported on Form 4 filed 2026-09-17). Filing appears timely (next‑day filing).
• Shares sold: 30,779; weighted average sale price: $20.1319; total proceeds ≈ $619,640.
• Price range reported: $20.00 to $20.64. Per footnote, a full breakdown of share counts by price will be provided upon request.
• Footnote: Shares were sold pursuant to a Rule 10b5‑1 trading plan adopted on June 10, 2026.
• Shares owned after transaction: Not disclosed in the provided filing details.

Context

• Sales executed under a 10b5‑1 plan are pre‑arranged and typically reflect a preexisting trading schedule rather than contemporaneous insider views.
• For retail investors, purchases generally carry more signal value than routine insider sales; this report documents a scheduled sale by an executive.